Stereotactic radiotherapy for intrahepatic cholangiocarcinoma  

作　　者：Aditya Borakati Farid Froghi Ricky H Bhogal Vasileios K Mavroeidis 

机构地区：[1]Department of Surgery,The Royal London Hospital,Barts Health NHS Trust,London E11FR,United Kingdom [2]Department of HPB and Liver Transplantation Surgery,Royal Free Hospital NHS Foundation Trust,London NW32QG,United Kingdom [3]Department of Academic Surgery,The Royal Marsden NHS Foundation Trust,London SW36JJ,United Kingdom

出　　处：《World Journal of Gastrointestinal Oncology》2022年第8期1478-1489,共12页世界胃肠肿瘤学杂志（英文版）（电子版）

摘　　要：Intrahepatic cholangiocarcinoma(iCCA)is an aggressive malignancy with an increasing incidence worldwide and poor prognosis,despite several advances and continuous efforts to develop effective treatments.Complete surgical resection is the mainstay of treatment and offers a potentially curative option,but is only possible in less than a third of patients,owing to advanced disease.Chemotherapy is a well-established treatment in the adjuvant and palliative setting,however,confers limited benefit.Conventional radiotherapy is challenging due to local toxicity.With recent advances in stereotactic ablative radiotherapy(SABR),it is now possible to focus ablative beams of radiotherapy precisely aimed at tumours to minimise damage to surrounding viscera.This review details the history,technical background and application of SABR to iCCA,with directions for future research suggested.

关 键 词：CHOLANGIOCARCINOMA INTRAHEPATIC Stereotactic ablative radiotherapy Stereotactic body radiotherapy RADIOTHERAPY Liver cancer HEPATECTOMY 

分 类 号：R735.8[医药卫生—肿瘤] R730.55[医药卫生—临床医学]